Quick Answer
Cue Biopharma, Inc. reported Total Assets of $42.21 million for the year ending 2025.
- Cue Biopharma, Inc. showed an increase of +31.1% in Total Assets from 2024 to 2025.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $59.33 million | Q2 2018: $53.11 million | Q3 2018: $44.58 million | Q1 2019: $45.19 million | Q2 2019: $41.76 million | Q3 2019: $45.21 million | Q1 2020: $60.65 million | Q2 2020: $101.35 million | Q3 2020: $106.62 million | Q1 2021: $88.72 million | Q2 2021: $89.67 million | Q3 2021: $78.88 million | Q1 2022: $90.70 million | Q2 2022: $84.75 million | Q3 2022: $76.30 million | Q1 2023: $81.68 million | Q2 2023: $73.16 million | Q3 2023: $68.89 million | Q1 2024: $53.95 million | Q2 2024: $42.33 million | Q3 2024: $44.81 million | Q1 2025: $22.25 million | Q2 2025: $40.71 million | Q3 2025: $31.64 million.
- Over the full 9 years of available data (2017 to 2025), Cue Biopharma, Inc.'s Total Assets has declined by 37.0%.
- Historical annual values: Fiscal year 2025: $42.21 million | Fiscal year 2024: $32.19 million | Fiscal year 2023: $61.53 million | Fiscal year 2022: $91.28 million | Fiscal year 2021: $83.40 million | Fiscal year 2020: $99.53 million | Fiscal year 2019: $71.61 million | Fiscal year 2018: $45.36 million | Fiscal year 2017: $66.95 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: